Dr. Derendorf’s research is focused on dose optimization during drug development and clinical practice. His group performs preclinical and clinical pharmacokinetic studies (PK), frequently combined with microdialysis studies to measure local drug concentrations at sites of interest in the body. To assess drug activity and safety, appropriate pharmacodynamic biomarker studies (PD) are performed. The collected data is analyzed in integrated PK/PD-models which allow to identify optimum doses and simulation of various clinically relevant scenarios. Dr. Derendorf’s group works mainly with ant-infective agents, corticosteroids, analgesics and other CNS drugs. Another area of interest of Dr. Derendorf is the assessment of food and drug interactions, particularly with grapefruit juice.